Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
FL.13.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.4.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.26NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.37NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JQ.2.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.23.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DY.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.2.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LJ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LE.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MD.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.1.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.3.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.15.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.15.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.36 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.1.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.7 (Alpha)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
P.1 (Gamma)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.120.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.119.2 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.121 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-22381.5US
AY.14 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.119 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.46.2 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.114 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.54 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.20 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.42 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.62 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.113 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.4 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.43 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.98.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.127 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.83 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.4.2 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.3.3 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.28.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.5.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23154.8US
JN.1.7.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.4.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26313.4US
JN.1.65NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.39.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used